Is there still a place for radiotherapy in gastric cancer?

Joshi, 2021, Current treatment and recent progress in gastric cancer, CA A Cancer J Clin, 71, 264, 10.3322/caac.21657 Cancer Genome Atlas Research, 2014, Comprehensive molecular characterization of gastric adenocarcinoma, Nature, 513, 202, 10.1038/nature13480 Cristescu, 2015, Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes, Nat Med, 21, 449, 10.1038/nm.3850 Davidson, 2019, Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: results from a prospective clinical trial screening programme, Eur J Cancer, 122, 12, 10.1016/j.ejca.2019.09.003 Lin, 2015, Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas, Gut, 64, 1721, 10.1136/gutjnl-2014-308252 Smyth, 2020, Gastric cancer, Lancet, 396, 635, 10.1016/S0140-6736(20)31288-5 Smyth, 2017, Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy (MAGIC) trial, JAMA Oncol, 3, 1197, 10.1001/jamaoncol.2016.6762 Kohlruss, 2019, Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epstein-Barr virus infection and high- and low-microsatellite instability, J Pathol Clin Res, 5, 227, 10.1002/cjp2.137 Sohn, 2017, Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project, Clin Cancer Res, 23, 4441, 10.1158/1078-0432.CCR-16-2211 Derks, 2020, Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas, Ann Oncol, 31, 1011, 10.1016/j.annonc.2020.04.011 Parikh, 2019, Analysis of DNA damage response gene alterations and tumor mutational burden across 17,486 tubular gastrointestinal carcinomas: implications for therapy, Oncol, 24, 1340, 10.1634/theoncologist.2019-0034 McLaughlin, 2020, Inflammatory microenvironment remodelling by tumour cells after radiotherapy, Nat Rev Cancer, 20, 203, 10.1038/s41568-020-0246-1 Schernberg, 2018, Adjuvant chemoradiation for gastric carcinoma: state of the art and perspectives, Clin Transl Radiat Oncol, 10, 13, 10.1016/j.ctro.2018.02.005 Sharfo, 2018, Automated VMAT planning for postoperative adjuvant treatment of advanced gastric cancer, Radiat Oncol, 13, 74, 10.1186/s13014-018-1032-z Maconi, 2008, Role of symptoms in diagnosis and outcome of gastric cancer, World J Gastroenterol, 14, 1149, 10.3748/wjg.14.1149 Takeda, 2022, Palliative radiotherapy for gastric cancer bleeding: a multi-institutional retrospective study, BMC Palliat Care, 21, 52, 10.1186/s12904-022-00943-2 Yu, 2019, Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial, JAMA, 321, 1983, 10.1001/jama.2019.5359 Songun, 2010, Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial, Lancet Oncol, 11, 439, 10.1016/S1470-2045(10)70070-X Cunningham, 2006, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer, N Engl J Med, 355, 11, 10.1056/NEJMoa055531 Al-Batran, 2019, Lancet, 393, 1948, 10.1016/S0140-6736(18)32557-1 Bang, 2012, Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial, Lancet, 379, 315, 10.1016/S0140-6736(11)61873-4 Sakuramoto, 2007, Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine, N Engl J Med, 357, 1810, 10.1056/NEJMoa072252 Lee, 2012, Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial, J Clin Oncol, 30, 268, 10.1200/JCO.2011.39.1953 Park, 2015, Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses, J Clin Oncol, 33, 3130, 10.1200/JCO.2014.58.3930 Kim, 2016, The influence of metastatic lymph node ratio on the treatment outcomes in the adjuvant chemoradiotherapy in stomach tumors (ARTIST) trial: a phase III trial, J Gastric Cancer, 16, 105, 10.5230/jgc.2016.16.2.105 de Steur, 2021, Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial, Ann Oncol, 32, 360, 10.1016/j.annonc.2020.11.004 Park, 2021, A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 tria, Ann Oncol, 32, 368, 10.1016/j.annonc.2020.11.017 Lordick, 2021, Adjuvant radiotherapy for gastric cancer-end of the road?, Ann Oncol, 32, 287, 10.1016/j.annonc.2020.12.006 Lutz, 2019, The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma, Eur J Cancer, 112, 1, 10.1016/j.ejca.2019.01.106 Leong, 2015, TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG), BMC Cancer, 15, 532, 10.1186/s12885-015-1529-x Leong, 2017, TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG, Ann Surg Oncol, 24, 2252, 10.1245/s10434-017-5830-6 Lucovic, 2021, The feasibility of quality assurance in the TOPGEAR international phase III clinical trial of neoadjuvant chemoradiotherapy for gastric cancer (an intergroup trial of the AGITG/TROG/EORTC/CCTG), Int J Radiat Oncol Biol Phys, 111 Slagter, 2018, BMC Cancer, 18, 877, 10.1186/s12885-018-4770-2 Guckenberger, 2020, Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation, Lancet Oncol, 21, e18, 10.1016/S1470-2045(19)30718-1 Salati, 2019, Oligometastatic gastric cancer: an emerging clinical entity with distinct therapeutic implications, Eur J Surg Oncol, 45, 1479, 10.1016/j.ejso.2018.11.006 Kroese, 2022, Incidence and survival of patients with oligometastatic esophagogastric cancer: a multicenter cohort study, Radiother Oncol, 173, 269, 10.1016/j.radonc.2022.06.012 Kroese, 2022, Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe, Eur J Cancer, 164, 18, 10.1016/j.ejca.2021.11.032 Verstegen, 2020, Metastatic pattern in esophageal and gastric cancer: influenced by site and histology, World J Gastroenterol, 26, 6037, 10.3748/wjg.v26.i39.6037 Kroese, 2022, Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: a systematic review and meta-analysis, Eur J Cancer, 166, 254, 10.1016/j.ejca.2022.02.018 Runkel, 2021, Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival, BMC Surg, 21, 35, 10.1186/s12893-020-01035-9 Mendez Romero, 2021, The Dutch-Belgian registry of stereotactic body radiation therapy for liver metastases: clinical outcomes of 515 patients and 668 metastases, Int J Radiat Oncol Biol Phys, 109, 1377, 10.1016/j.ijrobp.2020.11.045 Mayinger, 2021, Benefit of replanning in MR-guided online adaptive radiation therapy in the treatment of liver metastasis, Radiat Oncol, 16, 84, 10.1186/s13014-021-01813-6 Yamaguchi, 2020, The effectiveness of proton beam therapy for liver metastatic recurrence in gastric cancer patients, Jpn J Clin Oncol, 50, 903, 10.1093/jjco/hyaa052